We are live on ! Find out more
RGNX icon

Regenxbio

168 hedge funds and large institutions have $1.04B invested in Regenxbio in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 72 increasing their positions, 54 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 54

20% more call options, than puts

Call options by funds: $7.94M | Put options by funds: $6.61M

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.94% less ownership

Funds ownership: 80.4%79.46% (-0.94%)

10% less funds holding

Funds holding: 186168 (-18)

31% less capital invested

Capital invested by funds: $1.51B → $1.04B (-$470M)

55% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 33

Holders
168
Holders Change
-18
Holders Change %
-9.68%
% of All Funds
3.68%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
15
Increased
72
Reduced
54
Closed
33
Calls
$7.94M
Puts
$6.61M
Net Calls
+$1.33M
Net Calls Change
+$2.72M
Name Holding Trade Value Shares
Change
Change in
Stake
VOYA Investment Management
26
VOYA Investment Management
Georgia
$9.38M +$1.96M +48,368 +22%
Principal Financial Group
27
Principal Financial Group
Iowa
$8.99M -$169K -4,165 -2%
Ameriprise
28
Ameriprise
Minnesota
$8.85M -$25.9K -640 -0.3%
Morgan Stanley
29
Morgan Stanley
New York
$7.05M -$2.18M -53,913 -21%
Charles Schwab
30
Charles Schwab
California
$6.86M +$278K +6,869 +4%
N
31
Nuveen
North Carolina
$6.45M -$711K -17,557 -9%
Citadel Advisors
32
Citadel Advisors
Florida
$5.56M +$4.96M +122,409 +362%
Macquarie Group
33
Macquarie Group
Australia
$5.3M
AG
34
Artal Group
Luxembourg
$5.16M
UBS AM
35
UBS AM
Illinois
$4.29M +$28K +691 +0.6%
PC
36
Pier Capital
Connecticut
$4.2M +$390K +9,637 +9%
Rafferty Asset Management
37
Rafferty Asset Management
New York
$4.15M +$852K +21,015 +22%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$4.02M +$1.41M +34,747 +44%
GH
39
GAM Holding
Switzerland
$3.97M
TCM
40
Tekla Capital Management
Massachusetts
$3.89M +$3.91M +96,447 +753%
Citigroup
41
Citigroup
New York
$3.61M +$423K +10,440 +11%
Hudson Bay Capital Management
42
Hudson Bay Capital Management
Connecticut
$3.19M +$3.63M +89,594 New
Legal & General Group
43
Legal & General Group
United Kingdom
$3.04M +$155K +3,830 +5%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$2.83M -$19.4K -480 -0.6%
Public Sector Pension Investment Board (PSP Investments)
45
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$2.83M +$470K +11,604 +17%
Bank of Montreal
46
Bank of Montreal
Ontario, Canada
$2.43M +$236K +5,825 +9%
Wells Fargo
47
Wells Fargo
California
$2.39M -$134K -3,296 -5%
PAM
48
Panagora Asset Management
Massachusetts
$2.32M +$2.64M +65,049 New
PAWC
49
P.A.W. Capital
Connecticut
$2.31M +$1.42M +35,000 +117%
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$2.25M +$1.68M +41,543 +191%

RGNX Hedge Fund Activity: Q3 2019 in Review

168 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2019, worth a combined $1.04B — down 31% from $1.51B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of RGNX and 15 opened new positions — a net loss of 18 holders — while 54 trimmed existing stakes and 72 added.

The largest buyer was Redmile Group, adding an estimated $39.3M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $18M sold.

  • 168 institutional investors held Regenxbio (RGNX) as of Q3 2019, down from 186 in Q2 2019.
  • Funds reported $1.04B of Regenxbio stock for Q3 2019, down 31% quarter-over-quarter.
  • 15 funds opened new Regenxbio positions in Q3 2019 and 33 closed out, a net change of -18 holders.
  • The largest Regenxbio buyer in Q3 2019 was Redmile Group, an estimated $39.3M added.
  • The largest Regenxbio seller in Q3 2019 was Renaissance Technologies, an estimated $18M sold.

Based on aggregated 13F filings for Q3 2019.